Risa J.  Lavizzo-Mourey net worth and biography

Risa Lavizzo-Mourey Biography and Net Worth

Director of Better Therapeutics
Dr. Risa Lavizzo-Mourey has served as a member of Better’s board of directors since April 2021. Dr. Lavizzo-Mourey was a professor at the University of Pennsylvania from 1986 until 2021, and served as the Robert Wood Johnson Foundation Professor of Health Equity and Health Policy from 2018 to 2021. Dr. Lavizzo-Mourey was the Chief Executive Officer of the Robert Wood Johnson Foundation from 2003 to 2017, where she spearheaded initiatives to reverse the childhood obesity epidemic, create an affordable and inclusive healthcare system, and address social factors associated with adverse health impacts. Dr. Lavizzo-Mourey also has extensive government experience in a wide range of roles from 1985 to 1998, including as a Co-Chair of the White House Health Care Reform Task Force and as an Advisory Committee Member on the President’s Advisory Commission on Consumer Protection and Quality in the Health Care Industry. Dr. Lavizzo-Mourey has served as an independent director for Intel (NYSE: INTC) since 2018, where she is a member of the nominating and governance committee, as an independent director for Merck (NYSE: MRK) since 2020, where she is a member of the compensation and benefits and governance committees, and as an independent director for General Electric (NYSE: GE) since 2017, where she sits on the governance and public affairs committee. Dr. Lavizzo-Mourey got her B.S. at the State University of New York, Stony Brook, her M.D. at Harvard University, and her MBA at the University of Pennsylvania. We believe Dr. Lavizzo-Mourey is well equipped to be a director of Better due to her wealth of knowledge and experience, including in functional and thought leadership, across the healthcare spectrum, and her work as a primary care physician and shaping health policy on a national level. Dr. Lavizzo-Mourey has demonstrated a passion for cognitive behavioral therapy, having been the driver behind Robert Wood Johnson Foundation’s strategic shift towards the behavioral space.

What is Risa J. Lavizzo-Mourey's net worth?

The estimated net worth of Risa J. Lavizzo-Mourey is at least $4.24 as of March 6th, 2019. Dr. Lavizzo-Mourey owns 42,446 shares of Better Therapeutics stock worth more than $4 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Lavizzo-Mourey may own. Learn More about Risa J. Lavizzo-Mourey's net worth.

How do I contact Risa J. Lavizzo-Mourey?

The corporate mailing address for Dr. Lavizzo-Mourey and other Better Therapeutics executives is 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036. Better Therapeutics can also be reached via phone at 415-887-2311 and via email at [email protected]. Learn More on Risa J. Lavizzo-Mourey's contact information.

Has Risa J. Lavizzo-Mourey been buying or selling shares of Better Therapeutics?

Risa J. Lavizzo-Mourey has not been actively trading shares of Better Therapeutics within the last three months. Most recently, on Tuesday, December 21st, Risa J. Lavizzo-Mourey bought 10,000 shares of Better Therapeutics stock. The stock was acquired at an average cost of $4.60 per share, with a total value of $46,000.00. Learn More on Risa J. Lavizzo-Mourey's trading history.

Who are Better Therapeutics' active insiders?

Better Therapeutics' insider roster includes Kevin Appelbaum (CEO), Andrew Armanino (Director), Elder Granger (Director), Mark Heinen (Insider), and Risa Lavizzo-Mourey (Director). Learn More on Better Therapeutics' active insiders.

Risa J. Lavizzo-Mourey Insider Trading History at Better Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2021Buy10,000$4.60$46,000.00View SEC Filing Icon  
See Full Table

Risa J. Lavizzo-Mourey Buying and Selling Activity at Better Therapeutics

This chart shows Risa J Lavizzo-Mourey's buying and selling at Better Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Better Therapeutics Company Overview

Better Therapeutics logo
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

2,000 shs

Average Volume

2,449,991 shs

Market Capitalization

$5,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89